Partnering

PhaseBio currently has multiple programs available for license. In addition our ELP platform which is available to partners that could benefit from a sustained release mechanism for their proteins and peptides of interest.

• ELASTIN-LIKE POLYPEPTIDE (ELP) TECHNOLOGY

Summary: PhaseBio’s proprietary technology platform for modulating pharmacokinetics has extensive clinical and pre-clinical experience. ELP is based on a naturally-occurring amino acid sequence, can be optimized for desired drug exposure and has broad utility across a wide-range of drug classes and therapeutic areas. ELP technology extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism, resulting in exposure of active molecules for periods of a week or longer from a single subcutaneous injection. Favorable safety-and-tolerability profile has been well-characterized in multiple clinical trials.

• Pemziviptadil – AN ANALOGUE OF VASOACTIVE INTESTINAL PEPTIDE (VIP)

Summary: Once-weekly treatment for Pulmonary Arterial Hypertension (PAH). Pemziviptadil is a subcutaneously-injected, sustained release analogue of the native human peptide vasoactive intestinal peptide (VIP) fused to our ELP biopolymer. VIP is a neurohormone that has vasodilatory, anti-inflammatory and anti-fibrotic activity, as well as positive effects on cardiac function. A Phase 2B trial was voluntarily stopped early due to COVID-19 impacts on manufacturing, associated drug supply and the rate of enrollment in the study; PhaseBio has elected to stop further development after a strategic review and will reprioritize resources towards pre-commercialization activities for bentracimab and the advancement of PB6440 for resistant hypertension. PB1046 remains available for partnering discussions.

• GLP-2-ELP

Summary: Once-weekly ELP product candidate for short bowel syndrome. A weekly GLP-2 (teduglutide genetically fused to ELP) could significantly improve patient acceptability and adherence for patients with short bowel syndrome. Preclinical data with GLP-2-ELP demonstrated a significantly greater effect on the small intestine in normal rats than with teduglutide.

• C-TYPE NATRIURETIC PEPTIDE

Summary: CNP-ELP once weekly product candidate for achondroplasia. A weekly CNP could significantly improve patient adherence compared to a daily injection, leading to improved outcomes. Pre-clinical data with CNP-ELP demonstrated a robust effect on linear growth in mice.

• GLP-1 Receptor Antagonist

Summary: Once weekly product candidate for hypoglycemia associated with hyperinsulinemia. Potential treatment for hypoglycemia associated with hyperinsulinemia; congenital hyperinsulinism or hyperinsulinemic hypoglycemia post bariatric surgery.

• PTH

Summary: PTH-ELP for hypoparathyroidism / hypocalcemia. A weekly PTH could significantly improve patient adherence, leading to improved outcomes.